For more than seventy years, the enzyme phosphofructokinase was understood as a faithful servant of cellular energy metabolism — a fixed landmark in the biochemistry of life. Researchers at the University of Surrey have now discovered that one of its subunits, Pfk2, quietly performs a second role: binding and unwinding RNA to govern when cells divide. The finding reframes a familiar molecule as a molecular diplomat between energy and growth, and invites the humbling question of how many other long-studied proteins carry secrets we have not yet thought to ask about.
Enzyme long studied for energy production has hidden role in cell division
Related Coverage
Researchers at Tohoku University developed molecular antennae that dramatically increase visible-light sensitivity in ph…
News-Medical · Sep 10 Harvard researchers map path to lifetime brain-wide neural recording technologyHarvard researchers published a technological roadmap for implantable microelectronics enabling brain-wide neural record…
Le Monde.fr · Sep 10 French researcher Emmanuel Mignot wins Lasker Award for narcolepsy breakthroughEmmanuel Mignot, a French psychiatrist at Stanford, receives the prestigious Lasker Award for decades of research into n…
Tribune Online · Sep 10 Why the UN's map correction matters: Decolonising perception, starting with Africa's true sizeAn opinion piece argues that the UN's adoption of the Equal Earth map over the Mercator projection represents a crucial …
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
This is a basic science discovery about enzyme function with no direct geopolitical implications; it has no bearing on international relations, power dynamics, or regional conflicts.
Economic Lens
Discovery of dual function in 70-year-old metabolic enzyme (PFK) with potential applications in cancer treatment and cell cycle regulation could drive biotech innovation and pharmaceutical development.
Long-term potential for improved cancer treatments and cell-cycle-related disease therapies; near-term impact minimal as research is in early stages; could reduce healthcare costs if therapies prove effective.
Potential acceleration of FDA approval pathways for novel cancer therapeutics; increased R&D tax incentives for biotech firms; possible patent framework discussions around enzyme-based therapies; regulatory guidance needed for RNA-targeting drug development.